Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Treat. Rev.

Title: Cancer treatment reviews

Publisher: Elsevier BV

ISSN (Electronic): 1532-1967

ISSN (Print): 0305-7372

Publication date (Electronic): May 2018

Volume: 66

Affiliations

[1 ] Sorbonne Paris Cité, Paris Decartes University, Hôpital Européen Georges-Pompidou, Paris, France. Electronic address: jtaieb75@gmail.com.

[2 ] Johannes-Gutenberg University, Mainz, Germany. Electronic address: markus.moehler@unimedizin-mainz.de.

[3 ] National Cancer Center Hospital, Tokyo, Japan. Electronic address: nboku@ncc.go.jp.

[4 ] Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jajani@mdanderson.org.

[5 ] Instituto Clinico Oncologico del Sur, Temuco, Chile. Electronic address: eduardo.yanez@icos.cl.

[6 ] University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: miniryu@amc.seoul.kr.

[7 ] Merck, Darmstadt, Germany. Electronic address: silke.guenther@merckgroup.com.

[8 ] EMD Serono, Billerica, MA, USA. Electronic address: vikram.chand@emdserono.com.

[9 ] Seoul National University College of Medicine, Seoul, South Korea. Electronic address: bangyj@snu.ac.kr.

Article

Publisher Item ID: S0305-7372(18)30038-0

DOI: 10.1016/j.ctrv.2018.04.004

PubMed ID: 29730461

SO-VID: 003ef154-0730-4117-9a8e-a19c5fdc51cd

History

Keywords: Gastric,Gastroesophageal junction,PD-1/PD-L1,Immunotherapy,Immune checkpoint inhibitors

Data availability:

Keywords: Gastric, Gastroesophageal junction, PD-1/PD-L1, Immunotherapy, Immune checkpoint inhibitors

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

Read this article at

Abstract

Related collections

Cancer Immunotherapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 178

Cited by 44